A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Learn more about:
Related Clinical Trial
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH) A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule ADCC Mediated B-Cell dEpletion and BAFF-R Blockade Liver Test Study of Using JKB-122 in AIH Patients Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Mycophenolate vs Azathioprin in Autoimmune Hepatitis Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Mindfulness – Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis. Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation Autoimmune Hepatitis in Pediatric Patients

Brief Title

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Official Title

A Randomized, Open-label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Brief Summary

      This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of
      autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042
      capsules administration for the treatment.

Study Phase

Phase 2

Study Type


Primary Outcome

Percentage of biochemical response after 12 weeks of treatment.

Secondary Outcome

 Percentage of biochemical response with the absence of glucocorticoid-related adverse events after 12 weeks of treatment.


Autoimmune Hepatitis


HR19042 Capsules

Study Arms / Comparison Groups

 12 mg HR19042 Capsules QD


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 30, 2022

Completion Date

March 30, 2024

Primary Completion Date

December 30, 2023

Eligibility Criteria

        Inclusion Criteria:

          1. 18 years old≤Female or male patients≤70 years old;

          2. Clinical-confirmed autoimmune hepatitis;

          3. Biopsy-confirmed autoimmune hepatitis;

          4. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 ×
             upper limit of normal (ULN);

          5. Willing and able to give informed consent and follow the protocols during the trial.

        Exclusion Criteria:

          1. Patients with other chronic liver diseases;

          2. Patients with liver cirrhosis;

          3. Patients with hepatic encephalopathy;

          4. Positive results in HIV-Ab/TP-Ab/hepatitis virus tests

          5. Severe chronic or active infection requiring systemic anti-infective therapy within 14
             days before screening;

          6. Patients with severe cardiovascular diseases;

          7. Patients with malignancy within the past 5 years;

          8. Patients received organ transplantation;

          9. Patients treated with any systemic corticosteroids within 3 months before screening;

         10. Patients treated with any systemic immunosuppressive drugs within the 6 months before




18 Years - 70 Years

Accepts Healthy Volunteers



, +0518-82342973, [email protected]

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Study Sponsor

, , 

Verification Date

July 2022